Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) Interest Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Interest Expenses for 8 consecutive years, with $61000.0 as the latest value for Q1 2026.

  • For Q1 2026, Interest Expenses fell 15.28% year-over-year to $61000.0; the TTM value through Mar 2026 reached $357000.0, up 41.67%, while the annual FY2025 figure was $370000.0, 48.59% up from the prior year.
  • Interest Expenses hit $61000.0 in Q1 2026 for Kymera Therapeutics, down from $90000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $108000.0 in Q2 2025 and bottomed at $36000.0 in Q3 2022.
  • Average Interest Expenses over 5 years is $61823.5, with a median of $59000.0 recorded in 2022.
  • Year-over-year, Interest Expenses crashed 48.57% in 2022 and then soared 77.05% in 2025.
  • Kymera Therapeutics' Interest Expenses stood at $59000.0 in 2022, then dropped by 11.86% to $52000.0 in 2023, then grew by 13.46% to $59000.0 in 2024, then surged by 52.54% to $90000.0 in 2025, then tumbled by 32.22% to $61000.0 in 2026.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $61000.0, $90000.0, and $98000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.